Recruiting

Lymph Cancer Research

Sponsor:

National Cancer Institute (NCI)

Code:

NCT01676805

Conditions

Hodgkin Disease

Lymphoma, Non-Hodgkin

Multiple Myeloma

Lymphomatoid Granulomatosis

Leukemia-Lymphoma, Adult T-Cell

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Background:

\- Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To develop these studies, researchers want to collect samples from people with cancer or precancer conditions of the lymph system. These conditions include multiple myeloma, different types of lymphoma, and adult leukemia/lymphoma. The samples collected will include blood, urine, bone marrow, and tumor and skin tissue.

Objectives:

\- To collect tissue samples to study different types of lymph cancer.

Eligibility:

\- Individuals at least 18 years of age who have a lymphoid cancer or precancer condition.

Design:

  • Participants will be screened with a physical exam and medical history.
  • Different samples will be collected for study. Blood samples will be collected at the initial testing. More blood samples will be collected at different treatment points. Other liquid samples include urine, bone marrow, and any abnormal fluid. Tumor tissue and skin tissue biopsies will also be collected for study.
  • Treatment will not be provided as part of this study.

Conditions

Hodgkin Disease

Lymphoma, Non-Hodgkin

Multiple Myeloma

Lymphomatoid Granulomatosis

Leukemia-Lymphoma, Adult T-Cell

Study ID

NCT01676805

Start date

Sep 21, 2012

Status verified date

Jul 29, 2026

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

  • LYMPHOID MALIGNANCIES/DISEASES: The following criteria apply only to patients with a known lymphoid malignancy or precursor

disease, as described:

INCLUSION CRITERIA:

  • Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy, including multiple myeloma, B-cell and T-cell lymphomas: including but not limited to diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL).
  • Confirmation of pathological diagnosis is required from the Laboratory of Pathology, NCI. Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care or required testing on an NIH research protocol will be used for diagnosis.
  • Age >= 18 years of age
  • Ability of patient or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document NOTE: Patients enrolling with a LAR must be co-enrolled on another study.

EXCLUSION CRITERIA:

  • Pregnant individuals will not be eligible.
  • Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, and/or pulmonary dysfunction.
  • Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.

NON-LYMPHOID MALIGNANCIES/DISEASES: The following criteria apply only to patients without a known lymphoid malignancy or precursor disease, as described:

INCLUSION CRITERIA:

-Patients without a known lymphoid malignancy or lymphoid precursor diagnosis who have a planned surgical procedure during which blood or normal lymph node(s)/tissue (i.e., those not with pre-determined likelihood of abnormality/ malignancy) may be obtained for research studies as part of this protocol.

Patient is appropriate to undergo the surgical procedure planned, and consented for the same, as needed. NOTE: This study will not evaluate eligibility of the patient for surgery.

  • Age >= 18 years of age
  • Must be able and willing to sign informed consent

EXCLUSION CRITERIA:

  • Pregnant individuals will not be eligible.
  • Other active malignancy. NOTE: Patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin as well as any in situ carcinoma are eligible. Patients with a malignancy that has been treated with curative intent and who are without evidence of disease for >=2 years will also be eligible at the discretion of the investigator.
  • Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.

Study Design

Enrollment

1295 participants

Anticipated

Interventions and Outcome Measures

Arms

1

Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy

2

Patients without a known lymphoid malignancy or precursor disease to a lymphoid malignancy

Primary outcome measure

  • sample acquisition [ Time Frame: ongoing ]

Central Contacts and Locations

Central contacts

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

Contacts

For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

800-411-1222ccopr@nih.gov

More Information

Sponsor

National Cancer Institute (NCI)

Last update posted

Sep 1, 2026

Last verified

Jul 29, 2026

Keywords

  • Developing Novel Treatment Approaches
  • Developing Therapeutic Agents
  • Analysis of Genetic and Genomic Biology
  • New Prognostic and Diagnostic Models
  • Analysis of Cellular and Molecular Biology
  • Natural History

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-09-01.